Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438908 | 0.81 | KDM5B (0.42) | KDM5AKDM4CKDM5BPOLBMAPT | |
| SCHEMBL22718249 | 0.81 | KDM5B (0.42) | KDM5AKDM4CKDM5BPOLBMAPT | |
| SCHEMBL31308740 | 0.80 | CYP2E1 (0.35) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL18344826 | 0.79 | KDM5A (0.35) | KDM5AKDM5BCPB2 | |
| SCHEMBL14481327 | 0.77 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL16033755 | 0.75 | TK2 (0.37) | CYP2D6CYP2C9CYP2C19CYP19A1CYP1A2 | |
| SCHEMBL4289951 | 0.74 | CYP19A1 (0.57) | NPC1RAB9ACYP19A1 | |
| SCHEMBL369217 | 0.73 | SIRT2 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL24962037 | 0.72 | CYP19A1 (0.58) | HPGDSCYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL31544657 | 0.72 | CPB1 (0.33) | CYP3A4CYP2D6CYP2C9CYP2C19CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114466839-B | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2022-08-11 | — | — | US | disclosed |
| CN-114466839-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-110088104-B | Tetrahydropyridopyrimidine compounds for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3976194-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-10968218-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-3535261-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-20200062748-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3535261-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2019-09-11 | — | — | EP | disclosed |
| EP-2225243-B1 | Derivatives of N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2225243-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZOÝL,2- A¨PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009106751-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[L,2- A]PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885 |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885 |
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | IDH1, IDH2, XDH | HPGDS 2737/4885CYP3A4 362/4885CYP2D6 134/4885 |
| US-20200062748-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | DPYD, HAVCR2, TPMT | HPGDS 685/4885CYP3A4 22/4885CYP2D6 28/4885 |
| US-10968218-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, TPMT, TYMP | HPGDS 512/4885CYP3A4 27/4885CYP2D6 18/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | HPGDS 1573/4885CYP3A4 1648/4885CYP2D6 677/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | HPGDS 1259/4885CYP3A4 858/4885CYP2D6 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.